CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 50 enrolled
Drug / intervention
bendamustine hydrochloridedrug
Likely dose
bendamustine hydrochloride 120 mg/m2from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00984542
NCT00984542Phase 2Completed
CompareCT.gov

Phase II Study of Second-Line Bendamustine in Relapsed or Refractory Small Cell Lung Cancer (SCLC).

Vanderbilt-Ingram Cancer Center·interventional·Posted Sep 25, 2009·Updated Mar 12, 2014

In Brief

A Phase 2 clinical trial evaluating bendamustine hydrochloride for Lung Cancer. Completed, enrolled 50 participants across 6 sites.

Detailed Summary

RATIONALE: Drugs used in chemotherapy, such as bendamustine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well bendamustine works as second- or third-line therapy in treating patients with relapsed or refractory small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 25, 2009
Enrollment StartSep 1, 2009
Primary CompletionSep 1, 2012
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.8 years ago

Interventions

bendamustine hydrochloridedrug

Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle